Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Income Statement - Quarterly

Sep '21

Sep '22

Jun '23

Mar '24

Dec '24

Sep '25

Jun '26 (E)

Income Statement	Sep '25	Jun '25	Mar '25	Dec '24	Sep '24	Jun '24
Selling, General & Administrative Expenses	28.2	27.3	34	22.5	20.6	19
General and Administrative
Research & Development Expenses	141.2	184.4	187.6	167.5	157.6	314.8
Research and Development
Operating Profit	-169.4	-211.7	-221.6	-189.9	-178.2	-333.8
Loss from Operations
Non-Operating Income	-3.8	13.8	0.5	3.1	17.8	14.2
Other Expense, Net
Total Non-Operating Income	-3.8	13.8	0.5	3.1	17.8	14.2
Income Before Provision for Income Taxes	-173.2	-197.9	-221.1	-186.8	-160.4	-319.6
Loss Before Provision for Income Taxes
Provision for Income Taxes	0.2	0.3	0.6	0	-0.1	0.2
Provision for Income Taxes
Consolidated Net Income	-173.4	-198.1	-221.7	-186.8	-160.3	-319.8
Net Income Attributable to Common Shareholders	-173.4	-198.1	-221.7	-186.8	-160.3	-319.8
Net Loss
Basic EPS	-1.6	-1.9	-2.2	-1.9	-1.7	-3.6
Diluted EPS	-1.6	-1.9	-2.2	-1.9	-1.7	-3.6
Basic Weighted Average Shares Outstanding	105.8	102.4	101.9	101.1	94.4	87.8
Diluted Weighted Average Shares Outstanding	105.8	102.4	101.9	101.1	94.4	87.8
Total Shares Outstanding	105.8	105.8	102.1	101.2	94.9	92.3
EBITDA	-166.3	-209.7	-219.3	-187.5	-176.2	-331.8
Effective Tax Rate	-0.1%	-0.1%	-0.3%	-0%	0%	-0.1%